Chemotherapeutic Toxicity Clinical Trial
Official title:
The Effect of Home-Based Walking Program on Peripheral Neuropathy, Fatigue and Quality of Life in Patients Receiving Taxane and Platinum-Based Chemotherapy
The study aims to evaluate the effect of home-based walking program on peripheral neuropathy, fatigue and quality of life in patients receiving taxane and platinum-based chemotherapy.
Status | Recruiting |
Enrollment | 86 |
Est. completion date | September 30, 2024 |
Est. primary completion date | August 30, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria - 18 Years and older (Adult, Older Adult ) - Turkish speaking-understanding ability and literate. - Orientation (person, place, time) - Receiving taxane and platinum-based chemotherapy treatment (monotherapy or combined). - Receiving chemotherapy treatment for the first time. - The primary medical diagnosis is cancer (breast cancer, colorectal cancers and other cancers). - Not having health problems that prevent walking. - Agreeing to participate in the research. Exclusion Criteria - Being bone and brain metastases - Being peripheral neuropathy due to reasons other than chemotherapy (such as chronic disease, diabetes mellitus, nutritional disorders) - Skin sensitivity on the hands and feet - Having cardiovascular, pulmonary, musculoskeletal, or psychological disorders that limit exercise or mobility - Being in another supportive program - Being in the very active category according to the "International Physical Activity Scale (IPAQ- Short Form)" - Being a severity of more than 4 points according to the "Modified Borg Scale (MBS)" - Being a score of 2 and above according to the "ECOG Performance Scale" |
Country | Name | City | State |
---|---|---|---|
Turkey | Akdeniz University | Konyaalti | Antalya |
Lead Sponsor | Collaborator |
---|---|
Akdeniz University Hospital |
Turkey,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | International Physical Activity Questionnaire (IPAQ- Short Form) | It is used to evaluate physical activity. The form includes walking, moderate and vigorous activity, sitting categories. The total score includes the sum of time (minutes) and frequency (days). | Baseline and 8th week | |
Primary | National Cancer Institute (NCI) -CTCAE v5.0 Toxicity Criteria | This scale was developed to evaluate the grading of chemotherapy-related peripheral neurotoxicity. It evaluates sensory and motor neuropathy between grades 1-5. | Baseline and 8th week | |
Primary | Cancer Fatigue Scale | This scale was developed to evaluate the fatigue of cancer patients. It includes 15 questions and three sub-dimensions: Physical, Affective and Cognitive. The Likert type form is evaluated by giving points. Increasing scores received from the scale demonstrate a high level of fatigue. | Baseline and 8th week | |
Primary | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Chemotherapy-Induced Peripheral Neuropathy (EORTC QLQ-CIPN 20) | This scale was developed to evaluate the effect of peripheral neuropathy on quality of life of cancer patients. It includes 20 questions and three sub-dimensions: Sensory, Motor and Autonomic. The Likert type form is evaluated by giving points. Increasing scores received from the scale demonstrate a high level of symptoms and problems related to peripheral neuropathy. | Baseline and 8th week | |
Primary | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) | This Scale was developed to measure the quality of life of patients with cancer. It includes 30 questions and three sub-dimensions: Global health status, Functional, Symptom. High scores in the functional subscale indicate good/healthy functional status, high scores in the symptom subscale indicate high levels of symptoms and/or problems, and high scores in the global health status/quality of life subscale indicate good quality of life. | Baseline and 8th week |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04277650 -
System for High-Intensity Evaluation During Radiotherapy
|
N/A | |
Recruiting |
NCT05959720 -
Adult Acute Lymphoblastic Leukemia Treated With Pediatric Regimen in Brazil
|
||
Recruiting |
NCT06041477 -
Concurrently vs Sequentially Combined HAIC With Targeted and Immunotherapy in Potentially Resectable HCC
|
Phase 3 | |
Recruiting |
NCT06421610 -
OPC5: Pressurized IntraThoracic Aerosol Chemotherapy (PITAC) in Patients With Malignant Pleural Effusion.
|
Phase 1 | |
Recruiting |
NCT06197581 -
Safety Assessment of Concurrent Radiotherapy and Novel Systemic Therapy for Breast Cancer
|
N/A | |
Not yet recruiting |
NCT04965532 -
Residual Neuromuscular Block of Rocuronium in Chemotherapy Patients Under Sevoflurane Anesthesia
|
N/A | |
Completed |
NCT04843410 -
Effect of Exercise in the Management of Peripheral Neuropathy
|
N/A | |
Enrolling by invitation |
NCT04027478 -
Can Fasting Decrease the Side Effects of Chemotherapy?
|
N/A | |
Terminated |
NCT04607668 -
Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer (mCRC):
|
Phase 3 | |
Completed |
NCT05635929 -
Oral Mucositis and Quality of Life With a Mucosa Topical Composition in Head & Neck Cancer Patients.
|
N/A | |
Recruiting |
NCT06357871 -
Role of Renal Biopsy in the Suspicion of Nephrotoxicity of Immunotherapy (Checkpoint Inhibitors) in Solid Cancer
|
||
Completed |
NCT02996201 -
Electronic Patient Reporting of Side Effects to Chemotherapy: A Cluster Randomized Controlled Trial
|
N/A | |
Completed |
NCT00292526 -
Prevention of Chemotherapy-induced Cardiotoxicity in High-risk Patients
|
Phase 4 | |
Completed |
NCT04663178 -
Foot Bath and Chemotherapy Induced Fatigue
|
N/A | |
Recruiting |
NCT03191461 -
Myocardial Perfusion and Fibrosis in Cancer Survivors
|
||
Recruiting |
NCT05251922 -
Tolerance of Anti-Cancer Therapy in the Elderly
|
||
Not yet recruiting |
NCT06387901 -
Investigating Paclitaxel Toxicity in Breast Cancer: The Roles of Physical Activity and Body Composition.
|
||
Recruiting |
NCT05892146 -
Strategy Therapy on Cancer Therapy-Related Cardiac Dysfunction
|
N/A | |
Not yet recruiting |
NCT05921149 -
Fasting Mimicking Diet (FMD) in Conjunction With Chemotherapy in Advanced Ovarian Cancer
|
N/A | |
Recruiting |
NCT05302336 -
AC vs TC in Patients With HR-positive, HER2-negative Early Breast Cancer
|
Phase 4 |